Simultaneous targeting of PD-L1 and EGFR by bispecific antibodies promotes PD-L1 blockade selectively in the TME due to EGFR overexpression in malignant cells, while reducing potential off-tumor binding to normal PD-L1-expressing cells [35]. This evidence concerns the gene CD274 and neoplasm.